MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Regeneron Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

625.29 1.37

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

610.05

Max

627.04

Belangrijke statistieken

By Trading Economics

Inkomsten

-423M

918M

Verkoop

69M

3.8B

K/W

Sectorgemiddelde

16.529

63.778

EPS

12.07

Dividendrendement

0.56

Winstmarge

24.219

Werknemers

15,106

EBITDA

-534M

1.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+51.62% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.56%

2.39%

Volgende Winsten

29 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5B

70B

Vorige openingsprijs

623.92

Vorige sluitingsprijs

625.29

Nieuwssentiment

By Acuity

52%

48%

321 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Regeneron Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 feb 2025, 12:13 UTC

Winsten

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

8 jul 2024, 12:00 UTC

Winsten

Regeneron Expects Earnings Hit After $24 Million R&D Charge

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 11:58 UTC

Winsten

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb 2025, 11:37 UTC

Winsten

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb 2025, 11:37 UTC

Winsten

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb 2025, 11:36 UTC

Winsten

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb 2025, 11:35 UTC

Winsten

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 feb 2025, 11:35 UTC

Winsten

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 feb 2025, 11:34 UTC

Winsten

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 feb 2025, 11:34 UTC

Winsten

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 feb 2025, 11:32 UTC

Winsten

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 feb 2025, 11:31 UTC

Winsten

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 jan 2025, 08:30 UTC

Acquisities, Fusies, Overnames

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 jan 2025, 10:30 UTC

Top Nieuws

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 okt 2024, 13:58 UTC

Winsten

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 okt 2024, 10:52 UTC

Winsten

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 okt 2024, 10:34 UTC

Winsten

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 okt 2024, 10:33 UTC

Winsten

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 okt 2024, 10:33 UTC

Winsten

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31 okt 2024, 10:32 UTC

Winsten

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31 okt 2024, 10:30 UTC

Winsten

Regeneron Pharma 3Q Rev $3.72B >REGN

31 okt 2024, 10:30 UTC

Winsten

Regeneron Pharma 3Q EPS $11.54 >REGN

31 okt 2024, 10:30 UTC

Winsten

Regeneron Pharma 3Q Net $1.34B >REGN

25 okt 2024, 20:25 UTC

Winsten

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1 aug 2024, 11:50 UTC

Winsten

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 aug 2024, 10:37 UTC

Winsten

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 aug 2024, 10:30 UTC

Winsten

Regeneron Pharma 2Q EPS $12.41 >REGN

1 aug 2024, 10:30 UTC

Winsten

Regeneron Pharma 2Q Net $1.43B >REGN

1 aug 2024, 10:30 UTC

Winsten

Regeneron Pharma 2Q Rev $3.55B >REGN

Peer Vergelijking

Prijswijziging

Regeneron Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

51.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 948.55 USD  51.62%

Hoogste 1,182 USD

Laagste 575 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Regeneron Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

16

Buy

3

Hold

1

Sell

Technische score

By Trading Central

N/A / 662.33Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

321 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.